Vectura announces appointment of Jack Cashman to the position of Non-Executive Chairman of its Board of Directors
30 Mar 2001
Vectura announces appointment of Jack Cashman to the position of Non-Executive Chairman of its Board of Directors
Vectura Ltd today announced the appointment of Jack Cashman to the position of Non-Executive Chairman of its Board of Directors.
Jack Cashman has had extensive experience of managing industrial and healthcare companies in Europe and North America over the last thirty years. Of particular relevance to Vectura as an emerging drug delivery company is Jack Cashman's knowledge of this market sector from his eight years as the Executive Chairman and Co-CEO of RP Scherer Corporation, one of the world's largest international developers and manufacturers of drug delivery systems. Since leaving RP Scherer, he has participated in the leveraged buy-out of Amtrol Inc. (USA), a leading manufacturer of pressurised water systems, and has fulfilled the role of Executive Chairman of that company. He also has a number of non-executive Board appointments in the UK and Ireland.
Commenting on this appointment, Peter Virley, CEO of Vectura said, ' We are very pleased to have attracted someone with Jack's knowledge and experience of our specialist market sector to our Board. I hope we can create the same value for shareholders as we did working together at RP Scherer in the nineties.'
Vectura is a fast-growing drug delivery company specialising in the application of its core expertise in particle science to the development of unique technology platforms and enhanced-performance products of high commercial value. The company already has an established reputation as a leading European provider of innovative inhaler formulations for pulmonary delivery.
The company's Research and Development team is developing a range of unique, patent-protected drug delivery technology platforms, both in the pulmonary and other market sectors. These technology platforms will be designed to deliver drugs in a more cost-effective manner, thus enabling better life-cycle management opportunities for pharmaceutical companies as well as better treatment outcomes and greater satisfaction for patients,
Vectura has targeted specific product development opportunities in areas of high market potential where the company can create a clear competitive edge from its technology and know-how in pulmonary delivery. These include opportunities in the treatment of chronic obstructive pulmonary disease, in pain management and in the systemic delivery of inhaled macromolecules, such as insulin.
Vectura employs over 100 people at its Chippenham site. Its major shareholders are the Merlin Fund L.P., the University of Bath and its management.
For further information please contact:
Vectura Limited
Peter Virley
Tel: +44 (0)1249 667700
Fax: +44 (0)1249 667701
Email: enquiries@vectura.com
Financial Dynamics
David Yates / Lucy Briggs
Tel: + 44 (0) 207 269 7242
